Chronix Biomedical: Changes in Tumor Cell-Free DNA Copy Number Instability (CNI) Predict Therapeutic Response to Immunotherapy

SAN JOSE, Calif. & GÖTTINGEN, Germany–(BUSINESS WIRE)–Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA (‘cfDNA’) as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer. The abstract published today, “Tumor cell-free DNA copy number instability (CNI) predicts therapeutic respo
Source: BusinessWire-Primary

Chronix Biomedical: Changes in Tumor Cell-Free DNA Copy Number Instability (CNI) Predict Therapeutic Response to Immunotherapy